Credit Agricole S A Sells 706 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Credit Agricole S A reduced its stake in Alnylam Pharmaceuticals by 17.7% in the first quarter, now holding 3,287 shares valued at approximately $888,000.
• Multiple analysts have recently upgraded their ratings and price targets for Alnylam Pharmaceuticals, with a consensus target price of $405.33 and a strong "buy" sentiment from the majority.
• Alnylam Pharmaceuticals reported a $0.32 EPS for the last quarter, surpassing analyst expectations, and noted a 17.3% increase in revenue year-over-year.

Credit Agricole S A lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 17.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,287 shares of the biopharmaceutical company's stock after selling 706 shares during the period. Credit Agricole S A's holdings in Alnylam Pharmaceuticals were worth $888,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of ALNY. Park Square Financial Group LLC bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $28,000. Whipplewood Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares in the last quarter. Colonial Trust Co SC bought a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $35,000. Finally, Washington Trust Advisors Inc. increased its position in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 61 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on ALNY shares. Needham & Company LLC increased their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Chardan Capital increased their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Scotiabank increased their price objective on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research report on Friday, August 1st. Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Finally, Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $336.00 to $359.00 and gave the stock a "buy" rating in a research report on Friday, July 11th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $405.33.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $454.38 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $469.81. The firm has a fifty day simple moving average of $360.65 and a 200 day simple moving average of $296.97. The stock has a market capitalization of $59.56 billion, a price-to-earnings ratio of -183.96 and a beta of 0.25. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773,689 billion during the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the prior year, the company posted ($0.13) earnings per share. The firm's revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 2,274 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the sale, the executive vice president owned 50,121 shares in the company, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 31,640 shares of the stock in a transaction on Friday, May 30th. The shares were sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the completion of the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at approximately $14,899,281.72. This represents a 39.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 108,531 shares of company stock valued at $41,087,238 in the last three months. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.